These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 23142085)

  • 1. Anti-anaerobic potential of ranbezolid: insight into its mechanism of action against Bacteroides fragilis.
    Mathur T; Kalia V; Barman TK; Singhal S; Khan S; Upadhyay DJ; Rattan A; Raj VS
    Int J Antimicrob Agents; 2013 Jan; 41(1):36-40. PubMed ID: 23142085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents.
    Ednie LM; Rattan A; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1143-7. PubMed ID: 12604558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.
    Kalia V; Miglani R; Purnapatre KP; Mathur T; Singhal S; Khan S; Voleti SR; Upadhyay DJ; Saini KS; Rattan A; Raj VS
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1427-33. PubMed ID: 19075051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and SAR of novel oxazolidinones: discovery of ranbezolid.
    Das B; Rudra S; Yadav A; Ray A; Rao AV; Srinivas AS; Soni A; Saini S; Shukla S; Pandya M; Bhateja P; Malhotra S; Mathur T; Arora SK; Rattan A; Mehta A
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4261-7. PubMed ID: 16054358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of an ofloxacin-metronidazole combination against anaerobic bacteria. Kinetics of the action of metronidazole against Bacteroides fragilis].
    Dubreuil L; Devos J; Beerens H; Romond C
    Pathol Biol (Paris); 1988 May; 36(5):488-92. PubMed ID: 3043345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.
    Hoellman DB; Lin G; Ednie LM; Rattan A; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1148-50. PubMed ID: 12604559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial therapy for anaerobic infections.
    Finegold SM
    Scand J Gastroenterol Suppl; 1984; 91():61-72. PubMed ID: 6588490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of cefoperazone, cefoperazone plus sulbactam, ciprofloxacin, clindamycin, metronidazole, and penicillin G against anaerobic bacteria in an animal model.
    Moody JA; Fasching CE; Sinn LM; Gerding DN; Peterson LR
    J Lab Clin Med; 1990 Feb; 115(2):190-5. PubMed ID: 1967626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of RBx 7644 (ranbezolid) on biofilm producing bacteria.
    Mathur T; Bhateja P; Pandya M; Fatma T; Rattan A
    Int J Antimicrob Agents; 2004 Oct; 24(4):369-73. PubMed ID: 15380263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
    Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
    Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).
    Snydman DR; Jacobus NV; McDermott LA; Golan Y; Hecht DW; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rihs JD; Yu VL; Venezia R; Finegold SM; Rosenblatt JE; Gorbach SL
    Clin Infect Dis; 2010 Jan; 50 Suppl 1():S26-33. PubMed ID: 20067390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
    Papaparaskevas J; Pantazatou A; Katsandri A; Legakis NJ; Avlamis A;
    Clin Microbiol Infect; 2005 Oct; 11(10):820-4. PubMed ID: 16153256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranbezolid, a novel oxazolidinone antibacterial: in vivo characterisation of monoamine oxidase inhibitory potential in conscious rats.
    Naruganahalli KS; Shirumalla RK; Bansal V; Gupta JB; Das B; Ray A
    Eur J Pharmacol; 2006 Sep; 545(2-3):167-72. PubMed ID: 16899241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of anaerobic infections: an overview.
    Finegold SM
    Scand J Infect Dis Suppl; 1985; 46():89-95. PubMed ID: 3865355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections.
    Aldridge KE
    Am J Surg; 1995 May; 169(5A Suppl):2S-7S. PubMed ID: 7755163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    J Antimicrob Chemother; 2005 Jun; 55(6):1024-8. PubMed ID: 15824092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aspoxicillin on anaerobic bacteria.
    Ueno K; Watanabe K; Bunai M; Kobayashi T; Aoki M; Maezawa I; Sakuma Y; Yoshida H; Yamaguchi T
    Jpn J Antibiot; 1985 Jun; 38(6):1516-28. PubMed ID: 3850132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of anaerobic bacteria in Auckland: 1991-1996.
    Shore KP; Pottumarthy S; Morris AJ
    N Z Med J; 1999 Nov; 112(1099):424-6. PubMed ID: 10678225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial activities of tosufloxacin against anaerobic bacteria and the electron micrograph of its bactericidal effects.
    Takahata M; Nishino T
    Chemotherapy; 1997; 43(3):153-8. PubMed ID: 9142454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.